Search form
Search
contact us
Navigation
home
boards
job ratings
cp wire
medtech news
pharmagather
catering
advertise
Legal Help
login/register
You are here
Home
»
companies
» pamrevlumab
pamrevlumab
FibroGen’s Duchenne drug misses mark in first large trial
FibroGen’s Duchenne drug misses mark in first large trial
BioPharma Dive
FibroGen
clinical trials
Duchenne Muscular Dystrophy
pamrevlumab
Flag link:
Duchenne muscular dystrophy: major trials and events to watch in 2023
Duchenne muscular dystrophy: major trials and events to watch in 2023
Clinical Trials Arena
DMD
Duchenne Muscular Dystrophy
clinical trials
gene therapy
FDA
Sarepta Therapeutics
SRP-9001
FibroGen
pamrevlumab
Capricor
CAP-1002
Santhera
ReveraGen
vamorolone
Flag link:
Upcoming events – Fibrogen and Alnylam look to broaden their horizons
Upcoming events – Fibrogen and Alnylam look to broaden their horizons
EP Vantage
FibroGen
roxadustat
pamrevlumab
Duchenne Muscular Dystrophy
givosiran
Alnylam
Flag link:
Latest Phase 2 Data Shows Pamrevlumab Reduces Rate of Progression in Idiopathic Pulmonary Fibrosis
Latest Phase 2 Data Shows Pamrevlumab Reduces Rate of Progression in Idiopathic Pulmonary Fibrosis
CP Wire
FibroGen
pamrevlumab
IPF
idiopathic pulmonary fibrosis
Flag link:
Latest Phase 2 Data Shows Pamrevlumab Reduces Rate of Progression in Idiopathic Pulmonary Fibrosis
FibroGen
pamrevlumab
idiopathic pulmonary fibrosis
Flag link:
